US Patent

US8450311 — Pharmaceutical compositions containing a fluoroquinolone antibiotic drug

Formulation · Assigned to Novartis AG · Expires 2029-05-29 · 3y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions containing a fluoroquinolone antibiotic drug, such as moxifloxacin hydrochloride, in a specific dosage form.

USPTO Abstract

Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.

Drugs covered by this patent

moxifloxacin-hydrochloride (MOXIFLOXACIN HYDROCHLORIDE)

Patent Metadata

Patent number: US8450311
Jurisdiction: US
Classification: Formulation
Expires: 2029-05-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.